https://www.selleckchem.com/products/nms-873.html
BACKGROUND Lower-grade gliomas (LGG) with isocitrate dehydrogenase (IDH1/2) mutations have long survival times making evaluation of treatment efficacy difficult. We investigated the volumetric growth rate of IDH mutant gliomas before and after treatment with established glioma therapies to determine whether a significant change in growth rate could be documented and perhaps be used in the future to evaluate treatment response to investigational agents in LGG trials. METHODS In this multicenter retrospective study, 230 adult patients wit